Craniomaxillofacial devices are surgical devices, most predominantly implants, used in craniomaxillofacial surgeries to treat injuries, defects, and diseases in the head, neck, face, jaws, and hard and soft tissues of the oral and maxillofacial region. For example, facial plastic surgery is a very common type of surgery used to rectify or modify physical features in the craniomaxillofacial region.
The market is driven by factors such as a high incidence of accidents and sports injuries, a growing number of CMF surgeries, increasing awareness among people, and a growing preference for non-invasive means of surgery. Moreover, rising healthcare expenditures are some other factors that influence the demand for market products. Further, the incorporation of technological advancements such as 3D printed implants used in cranial reconstructive surgery is increasing applications and influencing large scale adoption.
In January 2017, OSSDSIGN was awarded approval from the U.S. Food and Drug Administration (FDA) for its OSSDSIGN Cranial Implants. These fully customizable implants can have advantages, such as preventing infection. These benefits are expected to widen the market scope. Additionally, many key players are taking strategic initiatives to establish wider distribution systems to increase geographical reach and expand the product portfolio. On the other hand, the high cost of craniomaxillofacial surgeries is a major factor expected to restrain this growth during the forecast period.
The COVID-19 pandemic has caused havoc and has put the global healthcare network under tremendous pressure. The global COVID-19 pandemic has heavily impacted the market dynamics of craniomaxillofacial devices. According to an article published in the National Centre for Biotechnology and Information (NCBI), surgeons worldwide have postponed most of the CMF surgeries, which has impacted the revenue flow for the market leaders. These actions are taken to reduce the risk of patients being exposed to the infection. Due to the massive crisis of support and healthcare infrastructure, hospitals are fully dedicated to acting as intensive care units for COVID positive patients. Thus, overall, this has increased the market projectile for the craniomaxillofacial devices market.